Update on Exhaled Nitric Oxide in Clinical Practice

Chest. 2016 May;149(5):1340-4. doi: 10.1016/j.chest.2015.11.020. Epub 2015 Dec 12.

Abstract

Asthma is characterized by chronic airway inflammation. Fractional exhaled nitric oxide (Feno) has emerged as a marker of T-helper cell type 2-mediated allergic airway inflammation. Recent studies suggest a role for Feno testing as a point-of-care tool in the management of patients with asthma. This Topics in Practice Management article reviews current coverage and reimbursement issues related to Feno testing and provides an overview of pertinent recent studies.

Keywords: asthma; nitric oxide.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / therapeutic use
  • Asthma / diagnosis*
  • Asthma / drug therapy
  • Asthma / immunology
  • Biomarkers
  • Breath Tests / methods*
  • Humans
  • Inflammation
  • Insurance Coverage
  • Nitric Oxide / analysis*
  • Nitric Oxide / immunology
  • Point-of-Care Testing / economics
  • Reimbursement Mechanisms
  • Th2 Cells / immunology

Substances

  • Adrenal Cortex Hormones
  • Biomarkers
  • Nitric Oxide